15.361 articles found

Cardiac noradrenergic deficiency revealed by 18F-dopamine positron emission tomography identifies preclinical central Lewy body diseases.

Goldstein DS, Holmes C, Sullivan P, Lopez G, Gelsomino J, Moore S, Isonaka R, Wu T, Sharabi Y.

J Clin Invest · 2024-01-02

DOI: 10.1172/jci172460PMID: 37883190

Study protocol for the Heads-Up trial: a phase II randomized controlled trial investigating head-up tilt sleeping to alleviate orthostatic intolerance in Parkinson's Disease and parkinsonism.

van der Stam AH, de Vries NM, Shmuely S, Smeenk D, Rutten JH, van Rossum IA, de Bot ST, Claassen JA, Bloem BR, Thijs RD.

BMC Neurol · 2024-01-02

DOI: 10.1186/s12883-023-03506-xPMID: 38166676

Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial.

Jost ST, Aloui S, Evans J, Ashkan K, Sauerbier A, Rizos A, Petry-Schmelzer JN, Gronostay A, Fink GR, Visser-Vandewalle V, Antonini A, Silverdale M, Timmermann L, Martinez-Martin P, Chaudhuri KR, Dafsari HS, International Parkinson and Movement Disorders Society Non-Motor Parkinson’s Disease Study Group and EUROPAR.

JAMA Netw Open · 2024-01-02

DOI: 10.1001/jamanetworkopen.2023.52177PMID: 38236600

Changes of brain-derived neurotrophic factor (BDNF) levels after different exercise protocols: a systematic review of clinical studies in Parkinson’s disease

Check source for author details

Frontiers in physiology · 2024-01-01

Role of Animal Models in Parkinson's Disease (PD): What Role They Play in Preclinical Translational Research.

Srivastava R, Dilnashin H, Kapoor D, Aparna S, Heidarli E, Singh SP, Jain V.

CNS Neurol Disord Drug Targets · 2024-01-01

DOI: 10.2174/1871527322666230223150347PMID: 36815656

Neuroprotective Potential of Hesperidin as Therapeutic Agent in the Treatment of Brain Disorders: Preclinical Evidence-based Review.

Bansal K, Singh V, Singh S, Mishra S.

Curr Mol Med · 2024-01-01

DOI: 10.2174/1566524023666230320144722PMID: 36959141

Blood-brain Barrier and Neurovascular Unit Dysfunction in Parkinson's Disease: From Clinical Insights to Pathogenic Mechanisms and Novel Therapeutic Approaches.

Khor SLQ, Ng KY, Koh RY, Chye SM.

CNS Neurol Disord Drug Targets · 2024-01-01

DOI: 10.2174/1871527322666230330093829PMID: 36999187

Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients.

Ciocca M, Pizzamiglio C.

CNS Neurol Disord Drug Targets · 2024-01-01

DOI: 10.2174/1871527322666230330122444PMID: 37005519

The Effect of Different Types of Exercise on Sleep Quality and Architecture in Parkinson Disease: A Single-Blinded Randomized Clinical Trial Protocol.

Cristini J, Potvin-Desrochers A, Seo F, Dagher A, Postuma RB, Rosa-Neto P, Carrier J, Amara AW, Steib S, Paquette C, Roig M.

Phys Ther · 2024-01-01

DOI: 10.1093/ptj/pzad073PMID: 37354450

Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings.

Alborghetti M, Bianchini E, De Carolis L, Galli S, Pontieri FE, Rinaldi D.

Neural Regen Res · 2024-01-01

DOI: 10.4103/1673-5374.375299PMID: 37488838

Pre-clinical Aspects and Contemporary Treatments of Parkinson's Disease.

Chhabra P, Rishabh, Singla S, Choudhary S, Kohli S, Bansal N, Bansal S.

CNS Neurol Disord Drug Targets · 2024-01-01

DOI: 10.2174/0118715273258646230920074421PMID: 37815179

Patient and Family Outcomes of Community Neurologist Palliative Education and Telehealth Support in Parkinson Disease.

Kluger BM, Katz M, Galifianakis NB, Pantilat SZ, Hauser JM, Khan R, Friedman C, Vaughan CL, Goto Y, Long SJ, Martin CS, Dini M, McQueen RB, Palmer L, Fairclough D, Seeberger LC, Sillau SH, Kutner JS.

JAMA Neurol · 2024-01-01

DOI: 10.1001/jamaneurol.2023.4260PMID: 37955923